Perjeta (chemical name: pertuzumab) is approved by the U.S. Food and Drug Administration (FDA) to be used in combination with Herceptin (chemical name: trastuzumab), another targeted therapy medicine, and Taxotere (chemical name: docetaxel), a type of chemotherapy, to treat HER2-positive, metastatic breast cancer that hasn’t been treated with either Herceptin or chemotherapy yet. (Perjeta was called Omnitarg in earlier studies.)
Perjeta also has accelerated FDA approval to be used in combination with Herceptin and Taxotere before surgery to treat HER2-positive, early-stage (the cancer must be larger than 2 cm or cancer must be in the lymph nodes), inflammatory, or locally advanced-stage breast cancer with a high risk of metastasizing or becoming fatal.
Doctors call treatments given before surgery neoadjuvant treatments.
This neoadjuvant Perjeta regimen is the first and only neoadjuvant regimen approved by the FDA to treat breast cancer.
In this section you can learn more about: